In re CTI BioPharma Corp. Securities Litigation

www.CTIBioPharmaSecuritiesSettlement.com


Overview

WELCOME TO THE CTI BIOPHARMA CORP. SECURITIES LITIGATION WEBSITE

In re CTI BioPharma Corp. Securities Litigation, United States District Court for the Western District of Washington at Seattle, Case No. 2:16-cv-00216-RSL.

The information contained on this web page is only a summary of information presented in more detail in the Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Fairness Hearing; and (III) Motion for an Award of Attorneys’ Fees and Reimbursement of Litigation Expenses (the “Notice”). Because this website is just a summary, you should review the Notice for additional details.

The Court-appointed Lead Plaintiff, DAFNA LifeScience, LP and DAFNA LifeScience Select LP, on behalf of itself and the other members of the Settlement Class (defined below), has reached a settlement of this Action with CTI BioPharma Corp. (“CTI”) and the other defendants in the Action for $20,000,000 in cash that resolves all claims in the Action (the “Settlement”).

Following a hearing on February 1, 2018, the Court entered an Order and Final Judgment approving the Settlement as fair, reasonable and adequate, entered an order approving the Plan of Allocation for the proceeds of the Settlement, and entered an order awarding attorneys’ fees and reimbursement of litigation expenses to Plaintiffs’ Counsel.

If you are a member of the Settlement Class, your rights will be affected and you may be eligible for a payment from the Settlement. The Settlement Class consists of:

all persons or entities, who during the period from March 9, 2015 through February 9, 2016, inclusive (the “Class Period”), purchased or otherwise acquired any shares of CTI common stock, CTI Series N-1 Preferred Stock, or CTI Series N-2 Preferred Stock, other than shares of such securities that traded on an exchange outside the United States, and were damaged thereby, except for certain persons and entities who are excluded from the Settlement Class by definition (see, paragraph 22 of the Notice) or who requested exclusion pursuant to the instructions set forth in the Notice.

Please read the Notice to fully understand your rights.

If you are a member of the Settlement Class, in order to be potentially eligible to receive a payment under the Settlement, you must submit a Claim Form postmarked no later than February 20, 2018. Payments to eligible claimants will be made only after the completion of all claims processing. Please be patient, as this process will take some time to complete.


IMPORTANT DEADLINE:
February 20, 2018 Claim Filing Deadline. Claim Forms must be postmarked no later than February 20, 2018 to be eligible for a payment from the Settlement.

Notice

Learn more about the Settlement by downloading the Notice in this case.

Claim Form

To participate in the Settlement, please submit a Proof of Claim and Release Form Form (“Claim Form”):

For institutions filing on behalf of multiples beneficial owners:

Court Documents

Learn more about the Settlement by downloading the documents below.

Contact Us

If you have questions which are not answered by this website, please contact us at: 1-844-402-8599 or In re CTI BioPharma Corp. Securities Litigation c/o GCG P.O. Box 35100 Seattle, WA 98124-1100